ERVE-1

Across TCGA pan-cancer cohorts, ERVE-1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ERVE-1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ERVE-1 RNA is repressed in tumor relative to normal tissue. In most cancer types ERVE-1 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and LUAD are the cancer types where ERVE-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERVE-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	−3.083	<.001	12	view →
KIRP	Female	All	−2.855	<.001	11	view →
LUAD	Female	III,IV	−1.501	<.001	9	view →
LUSC	All	III,IV	−1.328	<.001	9	view →
KICH	Male	All	−2.393	<.001	8	view →
THCA	Male	All	−1.350	<.001	8	view →
LIHC	Male	All	−0.223	<.001	7	view →
BRCA	Female	All	−0.549	<.001	4	view →
ESCA	All	All	−1.131	.011	2	view →
STAD	All	IV	−1.119	.003	2	view →
UCEC	All	All	+0.714	.005	2	view →
PRAD	All	All	−0.688	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ERVE-1–KIRC

Open the KIRC breakdown →